{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 8 of 8 results
Class (Stereo):
CHEMICAL (ACHIRAL)
Pumitepa is a purine derivative patented by All-Union Scientific-Research Chemical-Pharmaceutical Institute as cancerolytic. Although the exact mechanism of action of pumitepa has yet to be fully elucidated, this agent appears to work through alkylation, thereby causing DNA damage and cell cycle arrest.
In in vitro studies, Pumitepa prolonged the mitotic cycle in human embryo fibroblasts by 2.5-3 hr, primarily by prolonging the start of phase G1. Pumitepa induced similar types of chromosomal aberrations in cells of all phases of the mitotic cycle. Chromosomes in phase S were the most sensitive for Pumitepa, followed by chromosomes in phases G1 and G2.
Status:
Investigational
Source:
Ter Arkh. 2005;77(8):60-4.: Not Applicable Human clinical trial Completed Arthritis, Psoriatic
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Prospidium is a diazoniadispiro(5.2.5.2)hexadecane derivative patented by All-Union Scientific-Research Chemical-Pharmaceutical Institute as an antitumor agent that does not inhibit hematopoiesis. In preclinical models, The injection of Prospidium to thyroidectomized and hypophysectomized rats inhibited tumor growth to a greater extent than in intact rats. Larynx and lung cancer, lymphogranulomatosis, leucosis, etc. can be successfully treated with Prospidium at doses of 60-120 mg daily.
Status:
Possibly Marketed Outside US
Source:
Azaphen by All-Union Scientific-Research Chemical-Pharmaceutical Institute
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Pipofezine (Azafen or Azaphen) is a tricyclic antidepressant (TCA) approved in Russia for the treatment of depression. It was introduced in the late 1960s and is still used today. Pipofezine has been shown to act as a potent inhibitor of the reuptake of serotonin. In addition to its antidepressant action, pipofezine has sedative effects as well, suggesting antihistamine activity. Other properties such as anticholinergic or antiadrenergic actions are less clear but are likely. The main advantage of Azafen compared with other tricyclic antidepressants is that this drug has a low toxic effect on the body, including the heart, and it does not block cholinergic receptors and does not change the activity of monoamine oxidase. The maximum concentration in the blood is reached after 1-2 hours after taking the drug. Absorbed in the gastrointestinal tract, metabolism occurs in the liver, and is excreted by Azaphene kidneys.
Status:
Possibly Marketed Outside US
Source:
Pirroksan by All-Union Scientific-Research Chemical-Pharmaceutical Institute
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Proroxan is a non-selective а-adrenoblocker. Proroxan was found to prevent the development of hypertensive crises and improve cerebral bioelectrical parameters in most of hypertensive patients. Proroxan has been used as an antihypertensive and in the treatment
of Ménière’s disease, motion sickness, and allergic dermatitis.
Status:
Investigational
Source:
Ter Arkh. 2005;77(8):60-4.: Not Applicable Human clinical trial Completed Arthritis, Psoriatic
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Prospidium is a diazoniadispiro(5.2.5.2)hexadecane derivative patented by All-Union Scientific-Research Chemical-Pharmaceutical Institute as an antitumor agent that does not inhibit hematopoiesis. In preclinical models, The injection of Prospidium to thyroidectomized and hypophysectomized rats inhibited tumor growth to a greater extent than in intact rats. Larynx and lung cancer, lymphogranulomatosis, leucosis, etc. can be successfully treated with Prospidium at doses of 60-120 mg daily.
Status:
Possibly Marketed Outside US
Source:
Pirroksan by All-Union Scientific-Research Chemical-Pharmaceutical Institute
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Proroxan is a non-selective а-adrenoblocker. Proroxan was found to prevent the development of hypertensive crises and improve cerebral bioelectrical parameters in most of hypertensive patients. Proroxan has been used as an antihypertensive and in the treatment
of Ménière’s disease, motion sickness, and allergic dermatitis.
Status:
Possibly Marketed Outside US
Source:
Azaphen by All-Union Scientific-Research Chemical-Pharmaceutical Institute
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Pipofezine (Azafen or Azaphen) is a tricyclic antidepressant (TCA) approved in Russia for the treatment of depression. It was introduced in the late 1960s and is still used today. Pipofezine has been shown to act as a potent inhibitor of the reuptake of serotonin. In addition to its antidepressant action, pipofezine has sedative effects as well, suggesting antihistamine activity. Other properties such as anticholinergic or antiadrenergic actions are less clear but are likely. The main advantage of Azafen compared with other tricyclic antidepressants is that this drug has a low toxic effect on the body, including the heart, and it does not block cholinergic receptors and does not change the activity of monoamine oxidase. The maximum concentration in the blood is reached after 1-2 hours after taking the drug. Absorbed in the gastrointestinal tract, metabolism occurs in the liver, and is excreted by Azaphene kidneys.
Status:
Possibly Marketed Outside US
Source:
Pirroksan by All-Union Scientific-Research Chemical-Pharmaceutical Institute
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Proroxan is a non-selective а-adrenoblocker. Proroxan was found to prevent the development of hypertensive crises and improve cerebral bioelectrical parameters in most of hypertensive patients. Proroxan has been used as an antihypertensive and in the treatment
of Ménière’s disease, motion sickness, and allergic dermatitis.